{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 39,
  "pageCount": 53,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "This is a page from a formal report or legal document, likely a congressional or investigative committee report.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/39",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-39",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "McKinsey has not provided documents to the Committee showing that it adequately disclosed any relationship with a specific pharmaceutical company in line with this policy.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49d-cb34eb247569",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.15,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "McKinsey’s policy on conflicts of interest also states that it “will seek to minimize the scope of disclosures to what is absolutely necessary.” The policy provides that unless McKinsey can avoid a conflict through internal processes, “the potential conflict will be reported ... to the public sector client’s Contracting Officer with a mitigation proposal.” The policy recognizes that disclosure may result in the contracting office determining that McKinsey is “conflicted from serving on the public sector engagement, or as part of the contracting process may require McKinsey to perform further measures to mitigate any OCI.”188",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b75cd2c-ada5-4d10-af02-e5feb320de7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.15,
        "y": 0.49
      },
      "kind": "paragraph",
      "text": "McKinsey has not provided documents to the Committee showing that it adequately disclosed any relationship with a specific pharmaceutical company in line with this policy. While McKinsey has stated that its “proposals to the FDA frequently mentioned the company’s and personnel’s experience with the pharmaceutical industry, making the FDA aware of this aspect of McKinsey’s work in the field,” McKinsey’s isolated and vague references to its private sector clients in the documents produced to the Committee did not lay out any information necessary to assess its conflicts with opioid manufacturers or convey its conflicts in the manner required by McKinsey’s firm policy, which states that the “potential conflict will be reported, as described below, to the public sector client’s Contracting Officer with a mitigation proposal.”189",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e51d97e-3ea3-4804-ae80-aab61fac6209",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.15,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "McKinsey provided the Committee with a detailed “Organizational Conflicts of Interest Policy” for raising and assessing conflicts in relation to government contracts under federal regulations. The stated purpose of that policy is to “ensure compliance with U.S. Government organizational conflict of interest (“OCI”) requirements.”186 The policy states that McKinsey’s standard to determine whether a business interest presents “even the appearance of an OCI is whether the business interest in question would cause a reasonable person with knowledge of the relevant facts to question the impartiality of [McKinsey] in performing work under the solicitation or task order in question.”187",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad0c8b6f-77f5-413c-90ff-ad31ed55bdb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.15,
        "y": 0.72
      },
      "kind": "source-note",
      "text": "186 MCK-HCOR-0352178, Page 1. 187 Id., Page 2. 188 Id., Pages 2 and 4. 189 Watchdog Urged to Probe McKinsey Over Work with FDA, Opioid Manufacturers, ABC News (Apr. 5, 2022) (online at https://abcnews.go.com/US/watchdog-urged-probe-mckinsey-work-fda-opioid-manufacturers/story?id=83869544); MCK-HCOR-0352178, Page 3. One of McKinsey’s technical proposals submitted to the FDA in 2019 contained a two-page biography for Mr. Smith, including a subsection explaining that Mr. Smith’s “Recent Relevant Experience” included leading a team “developing an abuse-deterrent technology for opioid analgesics” for a pharmaceutical company. MCK-HCOR-0341261, A-4. Mr. Smith’s biography does not list his numerous opioid-related engagements at Purdue over the past decade, does not disclose that he worked for FDA and Purdue simultaneously, and does not mention Purdue by name, despite the Massachusetts Attorney General filing a civil complaint against the company earlier that year and extensive reporting of that lawsuit. The project description also does not appear to match Mr. Smith’s experience at Purdue and potentially represents a description of his work for a different opioid company.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3f931ee-ede9-42f7-9f47-0052251bc154",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.11
      },
      "kind": "title",
      "text": "4. McKinsey Was Aware of Its Duties to Avoid and Disclose Conflicts of Interest Under Its Contracts and the FAR",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6bcb80a-9aaf-48ed-9c40-0210bd51f3a3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 53,
      "from": 29,
      "beatId": "1170eac2-9202-4b41-a53c-edbd934ded10",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document concludes with implications of McKinsey's actions and potential next steps for regulatory action.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 40,
      "from": 24,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "308c22ef-34f3-45b8-b50d-c273c6edeb88",
      "evidence": "The document presents the concerns of regulatory bodies through examples of McKinsey's actions and lack of disclosure.",
      "position": 1,
      "objective": "What are the concerns of regulatory bodies regarding McKinsey's conflicts of interest?",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}